Emboline, Inc., a privately held medical technology company developing embolic protection solutions for structural heart procedures, today announced positive results from its pivotal PROTECT H2H ...
Emboline's Emboliner system excels in a global trial, showing superior debris capture and procedural success in TAVR patients ...
A device designed to capture more TAVR procedural debris proves noninferior to an existing device in a large trial, but the ...
SANTA CRUZ, Calif., March 11, 2026 /PRNewswire/ -- Emboline, Inc., a privately held medical technology company focused on reducing stroke and ischemic damage during structural heart procedures such as ...
The question remains: what will it take to prove that any protection device is having a meaningful impact on stroke risk?
SANTA CRUZ, Calif., Oct. 23, 2025 /PRNewswire/ -- Emboline, Inc., a leading innovator in full-body embolic protection devices for transcatheter procedures, today announced completion of patient ...
Emboline expects that its technology designed to reduce stroke risk during structural heart procedures will launch in the US ...
PROTECT H2H is the first randomized IDE trial of an embolic protection device in TAVR to meet all primary and secondary safety and efficacy endpoints, representing a significant clinical and regulator ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results